The next checkpoints? Immuno-oncology upstart looks to find new ways to unleash T cells
With much of the research community in oncology focused on T cell regulators like LAG-3 to follow up on CTLA4 and PD-L1 in the hunt for new targets to quell cancer, a pair of investigators in Germany asked themselves a simple question.
If tumor cells express PD-L1 to inhibit T cells, what else can be found on the surface of these cells that block T cells?
The question spurred them to begin an ambitious tumor screening program for new targets. And their work has now inspired a startup, iOmx Therapeutics, which has put together a $44 million A round to back the first few years of preclinical work and at least one proof-of-concept study for a lead program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
